Angle PLC Appointment of Scientific Adviser (0430P)
June 03 2015 - 2:01AM
UK Regulatory
TIDMAGL
RNS Number : 0430P
Angle PLC
03 June 2015
For immediate release 3 June 2015
ANGLE plc ("the Company")
APPOINTMENT OF SCIENTIFIC ADVISER
ANGLE plc (AIM: AGL OTCQX: ANPCY), the specialist medtech
company, is pleased to announce the appointment of James M. Reuben,
PhD, MBA, as a Scientific Advisor to the Company with immediate
effect.
Dr Reuben is a Professor in the Department of Hematopathology,
Division of Pathology/Lab Medicine at The University of Texas MD
Anderson Cancer Center, Houston, Texas. He has conducted extensive
research on circulating tumor cell (CTC) subsets, including those
with epithelial and mesenchymal phenotypes and their clinical
relevance to minimal residual disease in breast cancer.
The University of Texas MD Anderson Cancer Center is one of the
world's most respected centres devoted exclusively to cancer
patient care, research, education and prevention. A different part
of MD Anderson is already working with ANGLE as a key opinion
leader in the field of colorectal cancer.
Dr Reuben is a leader in translational medicine at MD Anderson
and in particular in the area of CTCs and liquid biopsies, a key
area of medical development in which he has been working for many
years. Translational medicine is the field involved in taking new
research and getting it applied in the treatment of patients.
ANGLE Founder and Chief Executive, Andrew Newland,
commented:
"Jim Reuben has exceptional knowledge of circulating tumor
cells. He was one of the leading investigators in the earliest
studies on CTCs and has been very actively involved ever since. We
are delighted that he has joined ANGLE's Scientific Advisory Board
and believe his in-depth knowledge and understanding of CTCs and
wide network of contacts in the field will be of great benefit to
ANGLE as we drive towards the widespread adoption of the Parsortix
system in cancer care."
For further information:
ANGLE plc 01483 685830
Andrew Newland, Chief Executive
Ian Griffiths, Finance Director
Cenkos Securities
Stephen Keys, Dr Christopher
Golden (Nominated adviser)
Russell Kerr, Olly Baxendale
(Sales) 020 7397 8900
Buchanan
Mark Court, Sophie Cowles,
Jane Glover 020 7466 5000
For Frequently Used Terms, please see the Company's website on
http://www.angleplc.com/the-parsortix-system/glossary/
Notes for editors
About ANGLE plc www.angleplc.com
ANGLE is a specialist medtech company commercialising a
disruptive platform technology that can capture cells circulating
in blood, such as cancer cells, even when they are as rare in
number as one cell in one billion blood cells, and harvest the
cells for analysis.
ANGLE's cell separation technology is called the Parsortix
system and it enables a liquid biopsy (simple blood test) to be
used to provide the cells of interest. Parsortix is the subject of
granted patents in the United States, China and Australia and three
extensive families of patents are being progressed worldwide. The
system is based on a microfluidic device that captures cells based
on a combination of their size and compressibility. The Parsortix
system is established with strong positive evaluations from leading
cancer research centres and is working with these cancer centres to
demonstrate key applications. Parsortix has a CE Mark for Europe
and FDA authorisation is in process for the United States.
The analysis of the cells that can be harvested from patient
blood with ANGLE's Parsortix system has the potential to help
deliver personalised cancer care offering profound improvements in
clinical and health economic outcomes in the treatment and
diagnosis of various forms of cancer.
The global increase in cancer to a 1 in 3 lifetime incidence is
set to drive a multi $billion clinical market. The Parsortix system
is designed to be compatible with existing major medtech analytical
platforms and to act as a companion diagnostic for major pharma in
helping to identify patients that will benefit from a particular
drug and then monitoring the drug's effectiveness.
Now that the Parsortix system has been developed, ANGLE is
focused on its commercialisation in the market.
ANGLE has established formal collaborations with world-class
cancer centres and is working with these cancer centres to
demonstrate key applications for its Parsortix non-invasive cancer
diagnostic system as a liquid biopsy. Details are available here
http://www.angleplc.com/the-company/collaborators/
As well as cancer, the Parsortix technology has the potential
for deployment with several other important cell types in the
future.
ANGLE began trading on the AIM market of the London Stock
Exchange in March 2004 under the ticker symbol AGL. For further
information please visit: www.angleplc.com.
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCPKNDNPBKKCAK
Angle (LSE:AGL)
Historical Stock Chart
From Mar 2024 to Apr 2024
Angle (LSE:AGL)
Historical Stock Chart
From Apr 2023 to Apr 2024